Pharmacological induction of peroxisomes in peroxisome biogenesis disorders

Heming Wei, Stephan Kemp, Martina C. McGuinness, Ann B. Moser, Kirby D. Smith

Research output: Contribution to journalArticle

Abstract

Inherited aberrant peroxisome assembly results in a group of neurological diseases termed peroxisome biogenesis disorders (PBDs). PBDs include three major clinical phenotypes that represent a continuum of clinical features from the most severe form, Zellweger syndrome (ZS), through neonatal adrenoleukodystrophy (NALD) to the least severe form, infantile Refsum's disease (IRD). Somatic cell complementation studies have identified 13 PBD complementation groups, each representing a defect in a peroxisomal protein (peroxin) involved in peroxisome biogenesis. Most complementation groups include a range of clinical phenotypes. In this study, peroxisome numbers were determined in fibroblasts from 29 PBD (ZS, NALD, and IRD) patients, with various phenotypes from nine complementation groups, using antibodies against either a peroxisomal membrane protein (anti-Pex14p) or peroxisomal matrix proteins (anti-SKL). A correlation between the number of peroxisomes, determined with either antibody, and PBD phenotype was found, suggesting that induction of peroxisome number might have a favorable effect on PBD. After treatment of PBD fibroblasts with sodium 4-phenylbutyrate, a human peroxisome proliferator, there was an approximate twofold increase in peroxisome number. After 4-phenylbutyrate treatment, an increase in transcription of the adrenoleukodystrophy-related gene and the peroxin gene, PEX11α, was found in PBD fibroblasts. In NALD and IRD, but not ZS, fibroblasts there was an increase in very-long-chain fatty acid β-oxidation and plasmalogen concentrations, and a decrease in very-long-chain fatty acid concentrations. These data suggest that pharmacological agents that induce peroxisome proliferation, such as 4-phenylbutyrate, may have therapeutic potential in the treatment of PBD patients with milder phenotypes (NALD and IRD).

Original languageEnglish (US)
Pages (from-to)286-296
Number of pages11
JournalAnnals of Neurology
Volume47
Issue number3
DOIs
StatePublished - 2000

Fingerprint

Peroxisomes
Infantile Refsum's Disease
Peroxisomal Disorders
Pharmacology
Zellweger Syndrome
Phenotype
Fibroblasts
Fatty Acids
Plasmalogens
Adrenoleukodystrophy
Peroxisome Proliferators
Proteins
Peroxisome biogenesis disorders
Antibodies
Therapeutics
Membrane Proteins

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Pharmacological induction of peroxisomes in peroxisome biogenesis disorders. / Wei, Heming; Kemp, Stephan; McGuinness, Martina C.; Moser, Ann B.; Smith, Kirby D.

In: Annals of Neurology, Vol. 47, No. 3, 2000, p. 286-296.

Research output: Contribution to journalArticle

Wei, Heming ; Kemp, Stephan ; McGuinness, Martina C. ; Moser, Ann B. ; Smith, Kirby D. / Pharmacological induction of peroxisomes in peroxisome biogenesis disorders. In: Annals of Neurology. 2000 ; Vol. 47, No. 3. pp. 286-296.
@article{a22b72898c504f90a1df2bb920b96974,
title = "Pharmacological induction of peroxisomes in peroxisome biogenesis disorders",
abstract = "Inherited aberrant peroxisome assembly results in a group of neurological diseases termed peroxisome biogenesis disorders (PBDs). PBDs include three major clinical phenotypes that represent a continuum of clinical features from the most severe form, Zellweger syndrome (ZS), through neonatal adrenoleukodystrophy (NALD) to the least severe form, infantile Refsum's disease (IRD). Somatic cell complementation studies have identified 13 PBD complementation groups, each representing a defect in a peroxisomal protein (peroxin) involved in peroxisome biogenesis. Most complementation groups include a range of clinical phenotypes. In this study, peroxisome numbers were determined in fibroblasts from 29 PBD (ZS, NALD, and IRD) patients, with various phenotypes from nine complementation groups, using antibodies against either a peroxisomal membrane protein (anti-Pex14p) or peroxisomal matrix proteins (anti-SKL). A correlation between the number of peroxisomes, determined with either antibody, and PBD phenotype was found, suggesting that induction of peroxisome number might have a favorable effect on PBD. After treatment of PBD fibroblasts with sodium 4-phenylbutyrate, a human peroxisome proliferator, there was an approximate twofold increase in peroxisome number. After 4-phenylbutyrate treatment, an increase in transcription of the adrenoleukodystrophy-related gene and the peroxin gene, PEX11α, was found in PBD fibroblasts. In NALD and IRD, but not ZS, fibroblasts there was an increase in very-long-chain fatty acid β-oxidation and plasmalogen concentrations, and a decrease in very-long-chain fatty acid concentrations. These data suggest that pharmacological agents that induce peroxisome proliferation, such as 4-phenylbutyrate, may have therapeutic potential in the treatment of PBD patients with milder phenotypes (NALD and IRD).",
author = "Heming Wei and Stephan Kemp and McGuinness, {Martina C.} and Moser, {Ann B.} and Smith, {Kirby D.}",
year = "2000",
doi = "10.1002/1531-8249(200003)47:3<286::AID-ANA3>3.0.CO;2-B",
language = "English (US)",
volume = "47",
pages = "286--296",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Pharmacological induction of peroxisomes in peroxisome biogenesis disorders

AU - Wei, Heming

AU - Kemp, Stephan

AU - McGuinness, Martina C.

AU - Moser, Ann B.

AU - Smith, Kirby D.

PY - 2000

Y1 - 2000

N2 - Inherited aberrant peroxisome assembly results in a group of neurological diseases termed peroxisome biogenesis disorders (PBDs). PBDs include three major clinical phenotypes that represent a continuum of clinical features from the most severe form, Zellweger syndrome (ZS), through neonatal adrenoleukodystrophy (NALD) to the least severe form, infantile Refsum's disease (IRD). Somatic cell complementation studies have identified 13 PBD complementation groups, each representing a defect in a peroxisomal protein (peroxin) involved in peroxisome biogenesis. Most complementation groups include a range of clinical phenotypes. In this study, peroxisome numbers were determined in fibroblasts from 29 PBD (ZS, NALD, and IRD) patients, with various phenotypes from nine complementation groups, using antibodies against either a peroxisomal membrane protein (anti-Pex14p) or peroxisomal matrix proteins (anti-SKL). A correlation between the number of peroxisomes, determined with either antibody, and PBD phenotype was found, suggesting that induction of peroxisome number might have a favorable effect on PBD. After treatment of PBD fibroblasts with sodium 4-phenylbutyrate, a human peroxisome proliferator, there was an approximate twofold increase in peroxisome number. After 4-phenylbutyrate treatment, an increase in transcription of the adrenoleukodystrophy-related gene and the peroxin gene, PEX11α, was found in PBD fibroblasts. In NALD and IRD, but not ZS, fibroblasts there was an increase in very-long-chain fatty acid β-oxidation and plasmalogen concentrations, and a decrease in very-long-chain fatty acid concentrations. These data suggest that pharmacological agents that induce peroxisome proliferation, such as 4-phenylbutyrate, may have therapeutic potential in the treatment of PBD patients with milder phenotypes (NALD and IRD).

AB - Inherited aberrant peroxisome assembly results in a group of neurological diseases termed peroxisome biogenesis disorders (PBDs). PBDs include three major clinical phenotypes that represent a continuum of clinical features from the most severe form, Zellweger syndrome (ZS), through neonatal adrenoleukodystrophy (NALD) to the least severe form, infantile Refsum's disease (IRD). Somatic cell complementation studies have identified 13 PBD complementation groups, each representing a defect in a peroxisomal protein (peroxin) involved in peroxisome biogenesis. Most complementation groups include a range of clinical phenotypes. In this study, peroxisome numbers were determined in fibroblasts from 29 PBD (ZS, NALD, and IRD) patients, with various phenotypes from nine complementation groups, using antibodies against either a peroxisomal membrane protein (anti-Pex14p) or peroxisomal matrix proteins (anti-SKL). A correlation between the number of peroxisomes, determined with either antibody, and PBD phenotype was found, suggesting that induction of peroxisome number might have a favorable effect on PBD. After treatment of PBD fibroblasts with sodium 4-phenylbutyrate, a human peroxisome proliferator, there was an approximate twofold increase in peroxisome number. After 4-phenylbutyrate treatment, an increase in transcription of the adrenoleukodystrophy-related gene and the peroxin gene, PEX11α, was found in PBD fibroblasts. In NALD and IRD, but not ZS, fibroblasts there was an increase in very-long-chain fatty acid β-oxidation and plasmalogen concentrations, and a decrease in very-long-chain fatty acid concentrations. These data suggest that pharmacological agents that induce peroxisome proliferation, such as 4-phenylbutyrate, may have therapeutic potential in the treatment of PBD patients with milder phenotypes (NALD and IRD).

UR - http://www.scopus.com/inward/record.url?scp=0034059821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034059821&partnerID=8YFLogxK

U2 - 10.1002/1531-8249(200003)47:3<286::AID-ANA3>3.0.CO;2-B

DO - 10.1002/1531-8249(200003)47:3<286::AID-ANA3>3.0.CO;2-B

M3 - Article

C2 - 10716247

AN - SCOPUS:0034059821

VL - 47

SP - 286

EP - 296

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 3

ER -